PHARMACYCLICS INC (PCYC)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

PHARMACYCLICS INC SUNNYVALE, CA 94085-4521

Pharmacyclics focuses on the development of products that improve existing therapeutic approaches to cancer and atherosclerosis. Product candidates include Xcytrin (a cancer treatment; in Phase 3 clinical trials as of June 2004) and Antrin (an atherosclerosis treatment; completed Phase 1 clinical trials).

View SEC Filings from PCYC instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PCYC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PCYC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VAN DEN BROEK RICHARD

  • Director
0 2015-05-26 0

MEHTA MINESH

  • Director
0 2015-05-26 0

SMITH DAVID DUANE

  • Director
0 2015-05-26 0

BOOTH ROBERT F.

  • Director
0 2015-05-26 0

ZANGANEH MAKY CHIEF OPERATING OFFICER

  • Officer
0 2015-05-26 0

HALVORSON ERIC H

  • Director
0 2015-05-26 0

DUGGAN ROBERT W CHAIRMAN AND CEO

  • Officer
  • Director
  • 10% Owner
0 2015-05-26 0

TAN HEOW CHIEF QUALITY&TECH OPERATIONS

  • Officer
0 2015-05-26 0

CLARK KENNETH A

  • Director
0 2015-05-26 0

SONI MANMEET SINGH CHIEF FINANCIAL OFFICER

  • Officer
0 2015-05-26 0

TOMASELLO SHAWN CHIEF COMMERCIAL OFFICER

  • Officer
0 2015-05-26 0

FARDIS MARIA CHIEF OF ONCOLOGY OPS & ALLIAN

  • Officer
3,193 2014-11-13 0

LOVE RICHARD B GENERAL COUNSEL

  • Officer
205 2014-11-10 0

MCGREIVY JESSE CHIEF MEDICAL OFFICER

  • Officer
0 2014-08-07 0

BARI SAMINA SVP, CORP COMMUNICATIONS

  • Officer
0 2014-07-07 0

SJOVALL BOULTBEE PAULA S EVP, SALES AND MARKETING

  • Officer
12,585 2014-05-08 0

ERDTMANN RAINER M SR. VP, IR AND ADMIN

  • Officer
5,701 2014-04-30 0

OUTTEN MATTHEW VP, COMMERCIAL OPERATIONS

  • Officer
10,938 2014-04-30 0

HEMMI GREGORY SR. VP CHEMICAL OPERATIONS

  • Officer
No longer subject to file 2014-03-05 0

CHANG BETTY Y VP, RESEARCH/BIOLOGY

  • Officer
No longer subject to file 2014-03-04 0

LOURY DAVID J EXECUTIVE VP, TOXICOLOGY

  • Officer
1,628 2013-10-31 0

CRUM MICHAEL VICE PRESIDENT, U.S. SALES

  • Officer
327 2013-10-31 0

LEE DANA VP, CLINICAL DRUG SAFETY

  • Officer
231 2013-10-31 0

FAUST ELIZABETH VP MEDICAL AFFAIRS

  • Officer
327 2013-10-31 0

SUCHET CHRISTOPHER VP INFORMATION TECHNOLOGY

  • Officer
327 2013-10-31 0

RAY SUMITA CHIEF COMPLIANCE OFFICER

  • Officer
112 2013-10-31 0

GRAEF THORSTEN VP, CLINICAL SCIENCE

  • Officer
806 2013-10-31 0

BEAUPRE DARRIN VP, CLIN. MED. & EARLY DEV.

  • Officer
386 2013-10-31 0

SHEARER SCOTT T VP, GLOBAL QUALITY

  • Officer
0 2013-06-06 0

BOEHM KENNETH F. SVP, HUMAN RESOURCES

  • Officer
0 2013-05-13 0

KUNKEL LORI ANNE CHIEF MEDICAL OFFICER

  • Officer
2,842 2013-04-30 0

BUGGY JOSEPH J VP, RESEARCH

  • Officer
8,713 2013-04-30 0

CLOW FONG WANG VP BIOSTATISTICS DATA MGMT

  • Officer
4,024 2013-04-30 0

GAYKO URTE SR. VP, REGULATORY

  • Officer
406 2013-04-30 0

HUH CHRISTINE VP, HUMAN RESOURCES

  • Officer
4,921 2012-10-31 0

BRUMM JOSHUA T EVP, FINANCE

  • Officer
0 2012-10-26 0

HARDIMAN ROY C.

  • Director
0 2012-10-01 0

ANDERSON CYNTHIA VP, CLINICAL OPERATIONS

  • Officer
0 2012-09-24 0

ASBURY MARK VP AND GENERAL COUNSEL

  • Officer
1,427 2012-04-30 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
557,211 2012-02-10 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
8,574,445 2012-01-24 0

14159 CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
195,858 2012-01-24 0

HEDRICK ERIC VICE PRESIDENT

  • Officer
4,152 2011-12-02 0

FYFE GWEN A.

  • Director
0 2011-10-03 0

HAMDY AHMED MD CHIEF MEDICAL OFFICER

  • Officer
11,966 2011-04-29 0

RICE GLENN C

  • Director
0 2010-10-01 0

BAMDAD CYNTHIA

  • Director
0 2010-10-01 0

ADELMAN JASON T

  • Director
0 2010-10-01 0

KNIGHTON JAMES L

  • Director
0 2008-12-12 0

LEVY RICHARD M

  • Director
0 2008-10-01 0

GILBURNE MILES R

  • Director
140,000 2008-10-01 0

WHITE CHRISTINE ANNA

  • Director
0 2008-10-01 0

LOWDER JAMES N MD VP CLINICAL DEVELOPMENT

  • Officer
0 2008-07-24 0

LEA LEIV VP FIN & ADMIN & CFO

  • Officer
20,893 2008-04-30 0

MILLER RICHARD A MD PRES, CEO & DIRECTOR

  • Officer
  • Director
326,798 2008-03-18 0

ROHN WILLIAM R

  • Director
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments